Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Elranatamab has not been directly compared in a clinical trial with the main comparator, pomalidomide plus dexamethasone, which limits the strength of the evidence. Indirect comparisons suggest potential benefits in terms of progression-free survival (PFS) and overall survival (OS), but the lack of direct evidence and ongoing trials introduce significant uncertainty regarding its clinical effectiveness.
Cost effectiveness
The cost-effectiveness estimates for elranatamab are uncertain and likely above NICE’s acceptable thresholds. The committee noted that while elranatamab could be cost-effective with further evidence, current estimates do not support routine use without managed access.
Quality of life
The treatment is reported to provide psychological benefits and convenience due to its subcutaneous administration, which may improve patient quality of life. However, specific validated HRQoL data is not detailed in the document, leading to a moderate rating.
Supporting Domains
Safety and Adverse Effects
Elranatamab has a good safety profile, with manageable adverse events. The document indicates that it does not require steroids, which is a significant advantage over other treatments. However, the potential for infections necessitates monitoring and possible IVIg use.
Comparator Selection
The main comparator, pomalidomide plus dexamethasone, was not directly tested against elranatamab, which raises concerns about the validity of the comparisons made. The committee acknowledged that the indirect comparisons were not ideal.
Patient Population and Subgroups
The trial population is described as triple-class refractory, which is representative of a significant subgroup of patients with relapsed and refractory multiple myeloma. However, there are concerns about generalizability to all patients eligible for treatment.
Care Pathway Integration
Elranatamab can be integrated into existing treatment pathways with minor adjustments, such as monitoring for infections. Its subcutaneous administration also facilitates easier integration into clinical practice compared to intravenous treatments.
Resource Use and Cost Implications
The resource implications of elranatamab are significant, particularly regarding the potential need for IVIg and monitoring. The committee noted that the overall cost burden could be high, raising concerns about affordability.
Evidence Quality and Robustness
The evidence base is primarily from a phase 2 trial with ongoing studies, leading to concerns about the robustness and maturity of the data. The lack of a randomized controlled trial further limits the strength of the evidence.
Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding long-term outcomes and the impact of IVIg use. The committee noted that the evidence base is immature, which could lead to restricted use until further data is available.
